Neurocrine Biosciences | NBIX - Cash And Equivalent


Neurocrine Biosciences reported $340.2M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
AbbVie USD 5.63B 838M Sep/2025
Acadia Pharmaceuticals USD 847.02M 85.02M Sep/2025
Agios Pharmaceuticals USD 92.71M 11.84M Sep/2025
ALKERMES USD 616.45M 95.25M Sep/2025
Alnylam Pharmaceuticals USD 1.49B 376.56M Sep/2025
Amgen USD 9.13B 316M Dec/2025
Biogen USD 3.86B 1.1B Sep/2025
BioMarin Pharmaceutical USD 1.25B 36.29M Sep/2025
Cytokinetics USD 225.47M 150.53M Sep/2025
Dynavax Technologies USD 160.25M 61.15M Sep/2025
Exelixis USD 376.3M 211.87M Sep/2025
Gilead Sciences USD 5.14B 2.78B Jun/2025
Halozyme Therapeutics USD 419.66M 357.8M Sep/2025
Incyte USD 2.93B 508.08M Sep/2025
Ionis Pharmaceuticals USD 2.24B 1.94B Sep/2025
Neurocrine Biosciences USD 340.2M 76.2M Sep/2025
Pfizer USD 1.34B 295M Sep/2025
Prothena USD 330.84M 40.6M Sep/2025
Regeneron Pharmaceuticals USD 18.87B 16.36B Dec/2025
Repligen USD 748.75M 39.89M Sep/2025
Sarepta Therapeutics USD 613.08M 102.48M Sep/2025
Teva Pharmaceutical Industries USD 3.56B 1.35B Dec/2025
Ultragenyx Pharmaceutical USD 202.51M 36.4M Sep/2025
Vertex Pharmaceuticals USD 6.29B 95.8M Sep/2025